|
|
|
| The Research on Clinical Curative Effect and Safety of Bozhi Glycopeptide Injection in the Treatment of Large Areas of Psoriasis Vulgaris |
| WANG Yingquan |
| Yulin Second Hospital, Shanxi Yulin 719000, China |
|
|
|
|
Abstract Objective: To evaluate the clinical curative effect and safety of Bozhi Glycopeptide Injection in the treatment of large areas of psoriasis vulgaris. Methods: One hundred and six cases of patients with large areas of psoriasis vulgaris were randomly divided into the control group and treatment group, 53 cases in each group. The control group was given A citretin capsule 30mg, qd, orally, on the basis of the control group, the experimental group was treated with Shen Qi Bozhi Glycopeptide Injection 4ml, qd, intravenous drip. Before and after treatment, compared between the two groups of patients with serum tumor necrosis factorα (TNF- α), interleukin 6(IL-6) , interleukin 17A(IL-17A) levels, interleukin-22(IL-22), interferonγ(INF-γ) , vascular endothelial growth factor (VEGF) , soluble E selectin (sE-slelctin) , soluble intercellular adhesion molecule -1 (sICAM-1) , efficiency of treatment and incidence of adverse reactions. Results: After treatment, serum levels of TNF-α, IL-6, IL-17A, IL-22, INF-γ,VEGF, sE-slelctin, sICAM-1 in the control group respectively were(91.65±12.87) pg/mL,(89.76±11.08)pg/mL,(16.46±1.55)pg/mL,(45.23±6.11)pg/mL,(16.52±2.47)pg/mL,(152.34±20.08)pg/mL,(43.29±5.78)ng/mL,(117.21±10.29)μg/L,, the levels of the above indicators in the experimental group respectively were (49.57±7.02) pg/mL, (58.46±7.66)pg/mL,(10.75±1.23)pg/mL,(38.23±5.01)pg/mL,(9.75±1.32)pg/mL,(123.12±12.54)pg/mL,(29.55±4.21)ng/mL,(98.75±12.13)μg/L, compared with the control group, the serum levels of TNF-α, IL-6, IL-17A, IL-22, INF-γ, VEGF, sE-slelctin, sICAM-1 were lower in the experimental group (P<0.05). The treatment efficiency of the experimental group (90.58%) was significantly higher than that of the control group (67.92%) (P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups (P > 0.05). Conclusion: The Bozhi Glycopeptide Injection can significantly reduce the serum levels of TNF-α, IL-6, IL-17A, IL-22, INF-γ, VEGF, sE-slelctin and sICAM-1 in patients with large areas of psoriasis vulgaris, inhibit angiogenesis, improve clinical efficacy, and have high clinical efficacy and safety.
|
|
|
|
|
|
[1] 郭菲.银屑病的中医药研究进展[J].新疆医科大学学报,2012,35(4):428~431.
[2] 周兆坤.银屑病的治疗进展[J].医学综述,2014,20(2):291~294.
[3] 沈秀中,邱莹.薄芝糖肽静滴联合窄谱中波紫外线照射治疗进行期寻常型银屑病疗效观察[J].山东医药,2011,51(38):91~92.
[4] 中华医学会皮肤性病学分会银屑病学组.中国银屑病治疗指南(2008版)[J].中华皮肤科杂志,2009,42(3):213~214.
[5] 中国医师协会皮肤科医师分会中西医皮肤科亚专业委员会.中成药治疗寻常性银屑病专家共识(2014)[J].中华皮肤科杂志,2014,47(3):215~216.
[6] 任磊,夏梦,潘厚儒,等.micro RNA在银屑病中医证候研究中的应用前景[J].世界中医药,2015,9(8):1270~1275.
[7] 程琳,王强,李铁男,等.多烯磷脂酰胆碱联合薄芝糖肽治疗寻常型银屑病的疗效观察[J].中国实用医药,2013,8(13):64~65.
[8] 胡银娥,王斌,瞿伟,等.NB-UVB联合白芍总苷治疗银屑病的疗效及对某些细胞因子的影响[J].中国麻风皮肤病杂志,2012,28(4):251~253.
[9] 董淑英.寻常性银屑病患者血清白细胞介素-17和-22水平及其与预后的相关性[J].中国老年学,2016,36(5):1165~1166.
[10] 宋晗,汪利.银屑病患者皮损和血清中VEGF、sICAM-1的表达分析[J].中国实验诊断学,2015,19(7):1197~1198. |
|
|
|
2017, Vol. 23 
